Heidi S Melbostad1, Patrick D Savage, Katharine Mahoney, Diann E Gaalema, Philip A Ades, Donald S Shepard. 1. Vermont Center on Behavior and Health, University of Vermont, and Department of Psychiatry, Larner College of Medicine, University of Vermont, Burlington (Drs Melbostad, Gaalema, and Ades and Ms Mahoney); University of Vermont Medical Center, Burlington (Mr Savage and Dr Ades); and The Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts (Dr Shepard).
Abstract
PURPOSE: Provision of phase 2 cardiac rehabilitation (CR) has been directly impacted by coronavirus disease-19 (COVID-19). Economic analyses to date have not identified the financial implications of pandemic-related changes to CR. The aim of this study was to compare the costs and reimbursements of CR between two periods: (1) pre-COVID-19 and (2) during the COVID-19 pandemic. METHODS: Health care costs of providing CR were calculated using a microcosting approach. Unit costs of CR were based on staff time, consumables, and overhead costs. Reimbursement rates were derived from commercial and public health insurance. The mean cost and reimbursement/participant were calculated. Staff and participant COVID-19 infections were also examined. RESULTS: The mean number of CR participants enrolled/mo declined during the pandemic (-10%; 33.8 ± 2.0 vs 30.5 ± 3.2, P = .39), the mean cost/participant increased marginally (+13%; $2897 ± $131 vs $3265 ± $149, P = .09), and the mean reimbursement/participant decreased slightly (-4%; $2959 ± $224 vs $2844 ± $181, P = .70). However, these differences did not reach statistical significance. The pre-COVID mean operating surplus/participant ($62 ± $140) eroded into a deficit of -$421 ± $170/participant during the pandemic. No known COVID-19 infections occurred among the 183 participants and 14 on-site staff members during the pandemic period. CONCLUSIONS: COVID-19-related safety protocols required CR programs to modify service delivery. Results demonstrate that it was possible to safely maintain this critically important service; however, CR program costs exceeded revenues. The challenge going forward is to optimize CR service delivery to increase participation and achieve financial solvency.
PURPOSE: Provision of phase 2 cardiac rehabilitation (CR) has been directly impacted by coronavirus disease-19 (COVID-19). Economic analyses to date have not identified the financial implications of pandemic-related changes to CR. The aim of this study was to compare the costs and reimbursements of CR between two periods: (1) pre-COVID-19 and (2) during the COVID-19 pandemic. METHODS: Health care costs of providing CR were calculated using a microcosting approach. Unit costs of CR were based on staff time, consumables, and overhead costs. Reimbursement rates were derived from commercial and public health insurance. The mean cost and reimbursement/participant were calculated. Staff and participant COVID-19 infections were also examined. RESULTS: The mean number of CR participants enrolled/mo declined during the pandemic (-10%; 33.8 ± 2.0 vs 30.5 ± 3.2, P = .39), the mean cost/participant increased marginally (+13%; $2897 ± $131 vs $3265 ± $149, P = .09), and the mean reimbursement/participant decreased slightly (-4%; $2959 ± $224 vs $2844 ± $181, P = .70). However, these differences did not reach statistical significance. The pre-COVID mean operating surplus/participant ($62 ± $140) eroded into a deficit of -$421 ± $170/participant during the pandemic. No known COVID-19 infections occurred among the 183 participants and 14 on-site staff members during the pandemic period. CONCLUSIONS: COVID-19-related safety protocols required CR programs to modify service delivery. Results demonstrate that it was possible to safely maintain this critically important service; however, CR program costs exceeded revenues. The challenge going forward is to optimize CR service delivery to increase participation and achieve financial solvency.
Authors: Alexander Kulik; Marc Ruel; Hani Jneid; T Bruce Ferguson; Loren F Hiratzka; John S Ikonomidis; Francisco Lopez-Jimenez; Sheila M McNallan; Mahesh Patel; Véronique L Roger; Frank W Sellke; Domenic A Sica; Lani Zimmerman Journal: Circulation Date: 2015-02-09 Impact factor: 29.690
Authors: Hani Jneid; Daniel Addison; Deepak L Bhatt; Gregg C Fonarow; Sana Gokak; Kathleen L Grady; Lee A Green; Paul A Heidenreich; P Michael Ho; Corrine Y Jurgens; Marjorie L King; Dharam J Kumbhani; Samir Pancholy Journal: Circ Cardiovasc Qual Outcomes Date: 2017-10
Authors: Randal J Thomas; Gary Balady; Gaurav Banka; Theresa M Beckie; Jensen Chiu; Sana Gokak; P Michael Ho; Steven J Keteyian; Marjorie King; Karen Lui; Quinn Pack; Bonnie K Sanderson; Tracy Y Wang Journal: J Am Coll Cardiol Date: 2018-03-29 Impact factor: 24.094
Authors: Philip A Ades; Gary J Balady; Kathy Berra; Barry A Franklin; Victor Froelicher; Larry F Hamm; Leonard A Kaminsky; Mark A Williams Journal: J Cardiopulm Rehabil Prev Date: 2020-01 Impact factor: 2.081
Authors: Erik H Van Iterson; Luke J Laffin; Michael Crawford; Dale Mc Mahan; Leslie Cho; Umesh Khot Journal: J Cardiopulm Rehabil Prev Date: 2021-03-01 Impact factor: 3.646
Authors: Lindsey Anderson; Neil Oldridge; David R Thompson; Ann-Dorthe Zwisler; Karen Rees; Nicole Martin; Rod S Taylor Journal: J Am Coll Cardiol Date: 2016-01-05 Impact factor: 24.094
Authors: H M C Kemps; R W M Brouwers; M J Cramer; H T Jorstad; E P de Kluiver; R A Kraaijenhagen; P M J C Kuijpers; M R van der Linde; E de Melker; S F Rodrigo; R F Spee; M Sunamura; T Vromen; M E Wittekoek Journal: Neth Heart J Date: 2020-07 Impact factor: 2.854